Applied Filters
Myriad v Ambry: the BRCA battle continues
Myriad has failed to stop Ambry offering genetic tests using the BRCA1 or BRCA2 genes, but Ambry raised a substantial question about the validity of the claims of Myriad’s patents, as MaryAnne Armstrong reports.
Combating cancer: Apexigen and rabbit antibodies
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.
Burden of proof: US Supreme Court backs licensees
The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen.
Aiming high: Canadian biotech
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level.
Cellular Dynamics: cells to order
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.
Number crunching: the search for potential therapies
How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande.
Patenting diagnostic methods post-Myriad
The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports.
New horizons: biotech guidelines in Brazil
New guidelines for the examination of biotechnology inventions in Brazil provide useful support for applicants, as Gabriel Di Blasi and Alexandre Santos explain.
Room for improvement: enforcing data exclusivity provisions in Mexico
In Mexico, it can be tricky to protect data exclusivity, but prospective international agreements may provide a solution, as Jose Trigueros explains.
Enough is enough: sufficiency and technical contribution
In the life sciences sector, defending broad patent claims can be a tricky business, says Gordon Wright.
